Press Releases

Date Title and Summary
Toggle Summary Isis Pharmaceuticals and Merck Extend Hepatitis C Drug Discovery Collaboration for a Second Time
Toggle Summary Isis Pharmaceuticals Reports Preliminary Phase II Data On ISIS 2503 Plus Chemotherapy in Pancreatic Cancer
Toggle Summary Isis Pharmaceuticals' Ibis Therapeutics Division Awarded New $2.4 Million Government Contract to Advance Its Antibacterial Drug Discovery Program
Toggle Summary Issuance of Key Second-Generation Antisense Patent Further Strengthens Isis' Intellectual Property Estate
Toggle Summary Isis Pharmaceuticals Announces Adoption of Securities Trading Plan Under SEC Rule 10b5-1
Toggle Summary Isis Pharmaceuticals' GeneTrove Division Enters Into Target Validation Collaboration and Patent License Agreement With Pharmacia Corporation
Toggle Summary HepaSense Initiates Phase II Clinical Trial of ISIS 14803 in Hepatitis C
Toggle Summary Isis Pharmaceuticals Initiates Phase II Clinical Trial of ISIS 104838, A TNF-Alpha Inhibitor, in Rheumatoid Arthritis
Toggle Summary Dr. John C. Reed Elected to Isis Pharmaceuticals' Board of Directors
Toggle Summary Isis Pharmaceuticals Reports Phase II Study Results Of Topical Alicaforsen, ISIS 2302, in Psoriasis
Toggle Summary Isis Pharmaceuticals Changes Ticker Symbol
Toggle Summary Isis Pharmaceuticals' GeneTrove(TM) Division Initiates Target Validation Collaboration With Merck & Co., Inc.
Toggle Summary Isis Pharmaceuticals Announces Plans to Change Ticker to 'ISIS'
Toggle Summary Isis Pharmaceuticals Reports Financial Results And Highlights for the Year 2001
Toggle Summary Webcast Alert: Isis Pharmaceuticals, Inc. Announces Its Fourth Quarter Financial Results on the Web;
Toggle Summary Enrollment Completed in Major Lung Cancer Trial
Toggle Summary Isis Pharmaceuticals And Eyetech Pharmaceuticals Sign Intellectual Property License Agreement
Toggle Summary Isis Pharmaceuticals And Amgen Enter Into Target Validation And Patent License Agreement
©1999 - 2017 Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics™ is a trademark of Ionis Pharmaceuticals, Inc.